Diabetes is a leading global health and economic challenge, affecting over 800 million people worldwide, with over 80% ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...

12 The claims data and health check-up data were linked at the individual subject level for analysis. We first identified subjects with at least one recorded diagnosis of type 2 diabetes in their ...

There is increasing interest in finding drugs, known as gerotherapeutics, that can slow aging and help people live longer.

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

Prediabetes is a clinical inflection point and a modifiable risk state. Small shifts in care can translate to big shifts in ...

Weight gain was associated with worse glycemic, cardiovascular, and kidney outcomes regardless of treatment among patients with type 2 diabetes.

It was clear from that time onwards that type 2 diabetes is caused by too much fat building up within liver, then overspilling to the rest of the body - including the pancreas. This starts up a second ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

If you have type 2 diabetes, you’re at increased risk of heart disease. Fortunately, healthy changes you can make to manage diabetes can also benefit your heart.

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide, exenatide, and dulaglutide were 41% more effective at preventing ...